DRI shareholder files Rule 144 notice to sell 1,200 common shares
Rhea-AI Filing Summary
A shareholder of the company with symbol DRI filed a notice of proposed sale of 1,200 shares of common stock under Rule 144. The filing lists an aggregate market value of $236,964 for these shares and states that 115,139,249 common shares were outstanding. The shares came from restricted stock vesting on July 28, 2024 under a registered plan in exchange for services rendered. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE around January 6, 2026. Over the prior three months, the same seller reported selling 1,700 common shares on October 14, 2025 for gross proceeds of $313,786. The seller represents that they are not aware of undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
FAQ
What does the DRI Rule 144 filing disclose about planned share sales?
The filing shows a shareholder plans to sell 1,200 shares of DRI common stock under Rule 144, with an aggregate market value of $236,964, through a broker on the NYSE around January 6, 2026.
How many DRI shares are outstanding according to this Rule 144 notice?
The notice states that there were 115,139,249 shares of common stock outstanding at the time referenced in the filing.
How did the seller acquire the 1,200 DRI shares being sold under Rule 144?
The 1,200 shares were acquired as restricted stock vesting on July 28, 2024 under a registered plan, with the consideration described as services rendered.
Which broker and exchange are involved in the planned DRI share sale?
The filing lists Morgan Stanley Smith Barney LLC as the broker for the transaction, with the shares expected to be sold on the NYSE.
What DRI share sales has the same seller made in the past three months?
During the prior three months, the seller reported selling 1,700 DRI common shares on October 14, 2025, for gross proceeds of $313,786.
What representation does the seller make about DRI’s information in this notice?
The seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.